290 related articles for article (PubMed ID: 17000102)
21. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
22. Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target.
Ramírez AR; Guerra Y; Otero A; García B; Berry C; Mendiola J; Hernández-Zanui A; Chávez Mde L
Biotechnol Appl Biochem; 2009 Feb; 52(Pt 2):149-57. PubMed ID: 18471091
[TBL] [Abstract][Full Text] [Related]
23. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
[TBL] [Abstract][Full Text] [Related]
24. Sulfonyl-phenyl-ureido benzamidines; a novel structural class of potent antimalarial agents.
Leban J; Pegoraro S; Dormeyer M; Lanzer M; Aschenbrenner A; Kramer B
Bioorg Med Chem Lett; 2004 Apr; 14(8):1979-82. PubMed ID: 15050641
[TBL] [Abstract][Full Text] [Related]
25. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
26. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
27. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
28. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids.
Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G
ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467
[TBL] [Abstract][Full Text] [Related]
29. Development of a plasmepsin II fluorescence polarization assay suitable for high throughput antimalarial drug discovery.
Flotow H; Leong CY; Buss AD
J Biomol Screen; 2002 Aug; 7(4):367-71. PubMed ID: 12230891
[TBL] [Abstract][Full Text] [Related]
30. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
31. Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors.
Recacha R; Leitans J; Akopjana I; Aprupe L; Trapencieris P; Jaudzems K; Jirgensons A; Tars K
Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1531-9. PubMed ID: 26625296
[TBL] [Abstract][Full Text] [Related]
32. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
33. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
[TBL] [Abstract][Full Text] [Related]
34. Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II.
Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2003 Mar; 11(6):827-41. PubMed ID: 12614868
[TBL] [Abstract][Full Text] [Related]
35. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
36. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II.
Haque TS; Skillman AG; Lee CE; Habashita H; Gluzman IY; Ewing TJ; Goldberg DE; Kuntz ID; Ellman JA
J Med Chem; 1999 Apr; 42(8):1428-40. PubMed ID: 10212129
[TBL] [Abstract][Full Text] [Related]
37. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity.
Chen X; Chong CR; Shi L; Yoshimoto T; Sullivan DJ; Liu JO
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14548-53. PubMed ID: 16983082
[TBL] [Abstract][Full Text] [Related]
39. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease.
Domínguez JN; López S; Charris J; Iarruso L; Lobo G; Semenov A; Olson JE; Rosenthal PJ
J Med Chem; 1997 Aug; 40(17):2726-32. PubMed ID: 9276017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]